Skip to Content

Onivyde (irinotecan liposomal) Disease Interactions

There are 5 disease interactions with Onivyde (irinotecan liposomal):

Major

Irinotecan Liposomal (Includes Onivyde) ↔ Diarrhea

Severe Potential Hazard, Moderate plausibility

Applies to: Intestinal Obstruction, Diarrhea

Irinotecan liposomal can cause severe and life-threatening diarrhea. Do not administer Irinotecan liposomal to patients with bowel obstruction. It is recommended to withhold treatment with irinotecan liposomal for Grade 2-4 diarrhea and to initiate appropriate clinical measures for diarrhea of any severity. The dose of irinotecan liposomal should be reduced according to manufacturer indications following recovery to Grade 1 diarrhea. Care should be exercised when using this agent in patients at risk of diarrhea episodes.

Major

Irinotecan Liposomal (Includes Onivyde) ↔ Neutropenia

Severe Potential Hazard, Moderate plausibility

Applies to: Neutropenia, Sepsis, Fever

Irinotecan liposomal can cause severe or life-threatening neutropenia and fatal neutropenic sepsis. In patients receiving irinotecan liposomal in combination with 5-FU and LV, the incidence of Grade 3 or 4 neutropenia and neutropenic fever/neutropenic sepsis was higher among Asian patients compared to White patients. Individuals who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia. It is recommended to monitor complete blood cell counts on Days 1 and 8 of every cycle and more frequently if clinically indicated and to withhold treatment if the absolute neutrophil count is below 1500/mm ^3 or if neutropenic fever occurs. Therapy could be resumed when the ANC is 1500/mm^ 3 or above. The dose of irinotecan liposomal should be reduced according to manufacturer indications for Grade 3-4 neutropenia or neutropenic fever following a recovery in subsequent cycles. Care is recommended when using this agent in neutropenic patients and in those patients homozygous for the UGT1A1*28 allele.

Moderate

Irinotecan Liposomal (Includes Onivyde) ↔ Interstitial Lung Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Pulmonary Heart or Vascular Disease, Pulmonary Impairment

Irinotecan can cause severe and fatal interstitial lung disease (ILD). It is recommended to withhold treatment with irinotecan liposomal in patients with new or progressive dyspnea, cough, and fever, pending diagnostic evaluation and to discontinue treatment in patients with a confirmed diagnosis of ILD. Exercise caution when using this agent in patients presenting symptoms of dyspnea.

Moderate

Irinotecan Liposomal (Includes Onivyde) ↔ Liver Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

The metabolism of irinotecan liposomal has not been evaluated. Irinotecan is primary metabolized by the liver to a biologically active metabolite. The pharmacokinetic disposition of irinotecan liposomal in patients with hepatic impairment has not been formally assessed. Therapy with irinotecan liposomal should be administered cautiously to patients with or predisposed to compromised hepatic function. Clinical monitoring of hepatic function is recommended.

Moderate

Irinotecan Liposomal (Includes Onivyde) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Population pharmacokinetic analyses suggest that no dose adjustment of irinotecan liposomal is required for patients with mild-to-moderate renal impairment. Caution is recommended when using this agent in patients with severe renal impairment as there is insufficient data to assess its effect.

Onivyde (irinotecan liposomal) drug Interactions

There are 400 drug interactions with Onivyde (irinotecan liposomal)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide